Short-term Flt3L treatment effectively mobilizes functional macaque dendritic cells
- 9 April 2004
- journal article
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 75 (6) , 1102-1110
- https://doi.org/10.1189/jlb.1103588
Abstract
In vivo administration of soluble Flt3L increases dendritic cell (DC) numbers to favor improved DC targeting of vaccine antigens, augmenting vaccine efficiency. In addition to confirming the effectiveness of human Flt3L in macaques, we strove to determine the optimal regimen to elevate numbers of functional DCs. Circulating DCs were identified within lineage−human leukocyte antigen-DR+ cells, which comprised CD11c−CD123+ plasmacytoid DCs (PDCs) and CD123− cells including CD11c+CD123− myeloid DCs as well as CD11c−CD123− cells. Traditionally, DCs have been monitored 1–2 days after 10- to 14-day treatments with Flt3L (100 μg/kg/day). We demonstrate that although standard treatment increased macaque DC percentages, as little as 5–7 days of treatment was sufficient, if not more effective at mobilizing DCs. Moreover, DC frequency continued to escalate over the ensuing days, peaking at ∼4 days post 7 days of treatment and ultimately decreasing thereafter. As expected, there was a more pronounced increase in the percentages and actual numbers of CD123− cells (CD11c+ and CD11c− subsets) compared with PDCs. Flt3L-mobilized DCs exhibited slightly increased CD80/CD86 expression but typically still that of immature DCs and were resilient to freeze-thawing. Overnight culture activated the cells, up-regulating CD80/CD86 expression as well as interleukin-12 release, typically being boosted by CD40L. This was even more apparent for enriched DC cultures. These data verify that peak mobilization of large numbers of functional macaque DCs occurs a few days, not immediately, after short-term Flt3L dosing. This has important implications for improved DC-targeting vaccine strategies to prevent infection with human immunodeficiency virus and other pathogens.Keywords
Funding Information
- Elizabeth Glaser Pediatric AIDS Foundation
- NIH (R21 AI52060, R01 AI40877)
- TNPRC (RR00164)
- Elizabeth Glaser Scientist
This publication has 52 references indexed in Scilit:
- Dendritic cell subsets in blood and lymphoid tissue of rhesus monkeys and their mobilization with Flt3 ligandBlood, 2003
- Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class I Products and Peripheral CD8+ T Cell ToleranceThe Journal of Experimental Medicine, 2002
- Productive Infection of Plasmacytoid Dendritic Cells with Human Immunodeficiency Virus Type 1 Is Triggered by CD40 LigationJournal of Virology, 2002
- Prospects for Vaccine Protection Against HIV-1 Infection and AIDSAnnual Review of Immunology, 2002
- Infectious and Whole Inactivated Simian Immunodeficiency Viruses Interact Similarly with Primate Dendritic Cells (DCs): Differential Intracellular Fate of Virions in Mature and Immature DCsJournal of Virology, 2002
- Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12European Journal of Immunology, 2001
- Subsets of Human Dendritic Cell Precursors Express Different Toll-like Receptors and Respond to Different Microbial AntigensThe Journal of Experimental Medicine, 2001
- Interferons α and β as Immune Regulators—A New LookPublished by Elsevier ,2001
- The Dendritic Cell-T Cell Milieu of the Lymphoid Tissue of the Tonsil Provides a Locale in Which SIV Can Reside and Propagate at Chronic Stages of InfectionAIDS Research and Human Retroviruses, 1999
- FLT3 Ligand Induces the Generation of Functionally Active Dendritic Cells in MiceCellular Immunology, 1997